Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, to...
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The...
Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive the...
-Japan Tissue Engineering Co., Ltd.（J-TEC） announced that JACC, its autologous cultured cartilage product, has been granted approval by Japan’s N...
Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, announ...
BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced that the supplemental Biologics License Application (sBLA) for Leqembi Iqlik subcutaneo...
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing fo...
Ant Group announced a major upgrade to the PC platform of its AI-native health assistant, AQ, introducing DeepSearch for clinicians, a new capabili...
The phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitini...
-Bayer and Vanderbilt University Medical Center (VUMC) announced that they have entered a strategic five-year collaboration agreement to advance innovati...
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, announced that it recently held a Type B End-of-Phase meeting with the U.S. FDA...
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significant...
Ouroboros Family Founders Fund I, LP announced this week it will lead a $60 million Series A financing in Cytotheryx, Inc., a preclinical cell therapy comp...
2026 is already shaping up to be a historic year for brain health as the healthcare industry confronts an urgent reality: cognitive impairment, Alzheimer...
© 2026 Biopharma Boardroom. All Rights Reserved.
